{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:16Z","timestamp":1753891936470,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>A small group of patients with Kawasaki disease (KD) demonstrates resistance to standard therapy, putting them at high risk for an unfavorable prognosis, especially regarding coronary artery aneurysms. Although adding corticosteroids to first-line i.v. immunoglobulins (IVIGs) is considered beneficial, and despite timely treatment initiation, very young infants, in particular, can present an unfavorable clinical course. We report on a 3-month-old boy with a clinically severe KD phenotype involving the early development of giant coronary artery aneurysms. Because of his poor response to the first course of IVIG and prednisolone, we administered infliximab. His clinical condition improved after that, and his temperature dropped. Inflammatory markers however did not recover completely, and he remained subfebrile. In addition, as the coronary artery dimensions deteriorated, a second IVIG course was administered and prednisolone continued at the initial dosage. Although fever and routine inflammatory parameters normalized, close follow-up investigations revealed both still increasing coronary artery dimensions and renewed rise in inflammatory parameters, necessitating two more infliximab administrations in addition to continuous prednisolone. Because of the coronary artery dimensions (left anterior descending artery, 4.9\u2005mm, Z-score 11.1; right coronary artery 5.8\u2005mm, Z-score 15.5), dual platelet inhibitory therapy with ASA and later clopidogrel combined with low-molecular heparin was indicated. Four weeks after his initial KD diagnosis, we detected no renewed increase in inflammatory markers; at that time, we observed a slight reduction in coronary dimensions. In summary, despite timely guideline-fulfilling therapy, the prolonged clinical course of this very young infant with KD entailing the development of giant coronary artery aneurysms makes us question whether this age group may benefit from early, even more intense therapy.<\/jats:p>","DOI":"10.3389\/fped.2023.1210940","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T17:55:31Z","timestamp":1690566931000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Have we got the optimal treatment for refractory Kawasaki disease in very young infants? A case report and literature review"],"prefix":"10.3389","volume":"11","author":[{"given":"Robert","family":"Lersch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Mandilaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas","family":"Anselmino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus A.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(04)16814-1","article-title":"Kawasaki syndrome","volume":"364","author":"Burns","year":"2004","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIRCULATIONAHA.107.690875","article-title":"Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements","volume":"116","author":"McCrindle","year":"2007","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/adc.86.4.286","article-title":"Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research","volume":"86","author":"Brogan","year":"2002","journal-title":"Arch Dis Child"},{"key":"B5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of Kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburger","year":"1986","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(84)91504-6","article-title":"High-dose intravenous gammaglobulin for Kawasaki disease","volume":"2","author":"Furusho","year":"1984","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s00112-022-01490-z","article-title":"Updated recommendations for action according to the S2k guidelines on Kawasaki syndrome","volume":"170","author":"Hospach","year":"2022","journal-title":"Monatsschr Kinderheilkd"},{"key":"B8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/01.inf.0000202068.30956.16","article-title":"Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994\u20132003","volume":"25","author":"Belay","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00246-002-0063-1","article-title":"Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease","volume":"24","author":"Honkanen","year":"2003","journal-title":"Pediatr Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0022-3476(95)70344-6","article-title":"Kawasaki disease in infants less than one year of age","volume":"126","author":"Rosenfeld","year":"1995","journal-title":"J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s00431-022-04458-z","article-title":"Acute phase of Kawasaki disease: a review of national guideline recommendations","volume":"181","author":"Scherler","year":"2022","journal-title":"Eur J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/INF.0b013e3181e05564","article-title":"Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin","volume":"29","author":"Shirley","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.autrev.2018.01.024","article-title":"The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series","volume":"17","author":"Kone-Paut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13052-018-0536-3","article-title":"Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I\u2014definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase","volume":"44","author":"Marchesi","year":"2018","journal-title":"Ital J Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"173985","DOI":"10.1016\/j.ejphar.2021.173985","article-title":"Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis","volume":"899","author":"Li","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S2352-4642(21)00270-4","article-title":"Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial","volume":"5","author":"Burns","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.echo.2010.10.004","article-title":"New equations and a critical appraisal of coronary artery Z scores in healthy children","volume":"24","author":"Dallaire","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1161\/CIRCULATIONAHA.105.592865","article-title":"Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease","volume":"113","author":"Kobayashi","year":"2006","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12887-019-1695-0","article-title":"Kawasaki disease in infants less than one year of age: an Italian cohort from a single center","volume":"19","author":"Mastrangelo","year":"2019","journal-title":"BMC Pediatr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/INF.0000000000001923","article-title":"Failure to predict high-risk Kawasaki disease patients in a population-based study cohort in Germany","volume":"37","author":"Jakob","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jpids\/piw075","article-title":"Prediction of resistance to intravenous immunoglobulin in children with Kawasaki disease","volume":"7","author":"Bar-Meir","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1097\/INF.0000000000002810","article-title":"Anakinra and etanercept combination treatment in a child with severe, nonresponsive Kawasaki disease","volume":"39","author":"Walser","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/archdischild-2022-324467","article-title":"Clinical characteristics of patients with recurrent Kawasaki disease: a nationwide cohort study of 19 456 patients with minimum 3-year follow up","volume":"108","author":"Kim","year":"2023","journal-title":"Arch Dis Child"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1210940\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T17:55:35Z","timestamp":1690566935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1210940\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":23,"alternative-id":["10.3389\/fped.2023.1210940"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1210940","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"article-number":"1210940"}}